BRIEF-NOVAVAX INC SAYS POSITIVE TOP-LINE DATA FROM PHASE 1. *Positive top-line data from phase 1 trial of ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with matrix-m. *Trial demonstrated that ebola GP vaccine was highly immunogenic, well-tolerated and resulted in significant antigen dose-sparing.» Read More
Glenn Hutchins, North Island Advisory chairman, discusses the impact of Moore's law, as technical devices get smaller and smaller and become integrated into people's lives.
Just in time for the holidays, Google is throwing its money, brain power and technology at the humble spoon for people with tremors.
IBM announced it will invest $3 billion in chip research and development in hopes of finding a game-changing breakthrough.
CNBC visits the University of Manchester, U.K., where the world's lightest, thinnest and strongest material is being produced: graphene.
In the latest episode of "The Edge", CNBC takes a closer look at nano technology and potential industrial applications.
Dato Jespal Deol, CEO of Graphene Nanochem, explains that the group produces nano-material for a number of global blue-chip companies.
Alex Gunz, fund manager at Heptagon Capital, discusses the advances in the nanotechnology sector and where to invest.
Forget Apple, suggests celebrated bear Doug Kass of Seabreeze Partners. He likes these names instead.
What follows is a list of jobs that may be prevalent in the 21st century. What they all have in common is they offer prospects to those entering the workforce for the rest of the century.